Antimalarial drug development: Past to present scenario

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 12, 2009, Pages 1447-1469

  Dhanawat, Meenakshi ^a   Das, Nirupam ^a   Ramesh, C ^a   Nagarwal, ^a   Shrivastava, S K ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Antimalarials; Combination therapy; Drug resistance; Malaria; Vaccines

Indexed keywords

1,10 DIMETHYL 7,8,15,16 TETRAOXADISPIRO[5.2.5.2]HEXADECANE; 1,2,4 TRIOXANE DERIVATIVE; 4 AMINOQUINOLINE DERIVATIVE; 8 AMINOQUINOLINE DERIVATIVE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEETHER; ARTEFLENE; ARTELINIC ACID; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; CHALCONE DERIVATIVE; CHLOROQUINE; CHLORPROGUANIL PLUS DAPSONE; CYCLOGUANIL; FANCIDAR; FOLIC ACID ANTAGONIST; HALOFANTRINE; MALOPRIM; MEFLOQUINE; PAMAQUINE; PRIMAQUINE; PROGUANIL; PYRIMETHAMINE; QUININE; SULFADOXINE; TAFENOQUINE; TETRAOXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIMALARIAL ACTIVITY; CLINICAL TRIAL; COMPLEX FORMATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEART ARRHYTHMIA; HEMOLYSIS; HUMAN; KIDNEY FAILURE; MALARIA; MALARIA FALCIPARUM; METHEMOGLOBINEMIA; NEUROPSYCHIATRY; NONHUMAN; PLASMODIUM VIVAX MALARIA; PROPHYLAXIS; SHORT SURVEY; SIDE EFFECT; SUBSTITUTION REACTION; UNSPECIFIED SIDE EFFECT;

AMINOQUINOLINES; ANTIMALARIALS; BIOLOGICAL PRODUCTS; COORDINATION COMPLEXES; DRUG THERAPY, COMBINATION; FOLIC ACID ANTAGONISTS; HETEROCYCLIC COMPOUNDS; HUMANS; MALARIA; MALARIA VACCINES; PEROXIDES; TETRAOXANES;

EID: 74049101671     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709789957323     Document Type: Short Survey

References (171)

1. http://www.searo.who.int/LinkFiles/Reports-WMR-2008-Final.pd f.
2. Dondorp, A. M.; Kager, P. A.; Vreeken, J.; White, N. J. Abnormal blood flow and red blood cell deformability in severe malaria. Parasitol. Today, 2000, 16, 228-32.
3. www.iavireport.org/Issues/1102/malariavax.asp.
4. Ward, S. A.; Bray, P. G.; Mungthin, M.; Hawley, S. R. Current views on the mechanisms of resistance to quinoline-containing drugs in Plasmodium falciparum. Ann. Trop. Med. Parasitol., 1995, 89, 121-24.
5. Foote, S. J.; Cowman, A. F. The mode of action and the mechanism of resistance to antimalarial drugs. ActaTrop., 1994, 56, 157-71.
6. White. N.J. Antimalarial drug resistance, J. Clin. Invest., 2004, 113, 1084-92.
7. Richie, T.L.; Saul, A. Progress and challenges for malaria vaccines. Nature, 2002, 415, 694-701.
8. Ridley, R. G. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature, 2002, 415, 686-93.
9. Gardner, M. J.; Hall, N.; Fung, E.; White, O.; Berriman, M.; Hyman, R. W.; Carlton, J. M.; Pain, A.; Nelson, K. E.; Bowman, S.; Paulsen, I. T.; James, K.; Eisen, J. A.; Rutherford, K.; Salzberg, S. L.; Craig, A.; Kyes, S.; Chan, M. S.; Nene, V.; Shallom, S. J.; Suh, B.; Peterson, J.; Angiuoli, S.; Pertea, M.; Allen, J.; Selengut, J.; Haft, D.; Mather, M. W.; Vaidya, A. B.; Martin, D. M.; Fairlamb, A. H.; Fraunholz, M. J.; Roos, D. S.; Ralph, S. A.; McFadden, G. I.; Cummings, L. M.; Subramanian, G. M.; Mungall, C.; Venter, J. C.; Carucci, D. J.; Hoffman, S. L.; Newbold, C.; Davis, R. W.; Fraser, C. M.; Barrell, B. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature, 2002, 419, 498-511.
10. Rosenthal, P.J. Antimalarial drug discovery: old and new approaches. J. Exp. Biol., 2003, 206, 3735-44.
11. Sutherland, C.J. Comparing highly efficacious antimalarial drugs. PLoS Med., 2008, 5, e228.
12. Foley, M.; Tilley, L. Quinoline antimalarials: mechanisms of action and resistance and prospectus for new agents. Pharmacol. Ther., 1998, 79, 55-87.
13. Krishna, S.; White, N.J. Pharmacokinetics of quinine, chloroquine and amodiquine. Clinical implications. Clin. Pharmacokinet., 1996, 30, 263-99.
14. ter Kuile, F.; White, N.J.; Holloway,P.; Pasvol, G.; Krishna, S. Plasmodium falciparum in vitro studies of the pharmacodynamics properties of drugs used for the treatment of severe malaria. Exp. Parasitol., 1993, 76, 85-95.
15. Fidock, D.A.; Nomura. T.; Talley. A.K.; Cooper, R.A.; Dzekunov, S.M.; Ferdig, M.T.; Ursos, L.M.; Sidhu, A.B.; Naude, B.; Deitsch. K.W.; Su, X.Z.; Wootton, J.C.; Roepe, P.D.; Wellems, T.E. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol. Cell, 2000, 6, 861-71.
16. Cooper, R.A.; Ferdig, M.T.; Su, X.Z.; Ursos, L.M.; Mu, J.; Nomura, T.; Fujioka, H.; Fidock, D.A.; Roepe, P.D.; Wellems, T.E. Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. Mol. Pharmacol., 2002, 61, 35-42.
17. Tracy, J.W.; Webster, L.T. In Goodman & Gilman's The Pharmacological Basis of Therapeutics; Hardman, J.G.; Limbird, L.E., 10th Ed.; McGraw-Hill: New York, 2001; pp. 1077.
18. Seidlein, L.V.; Greenwood, B.M. Mass administrations of antimalarial drugs. Trends Parasitol., 2003, 19, 452-60.
19. Prabhakara, V.G.; Jayaraman, M.; Kamalam, A.; Yesudian, P. Chloroquine- induced photosensitive dermatoses. Indian J. Dermatol. Venereol. Leprol. 1996, 62, 165-66.
20. Ayad,F.; Tilley,L.; Deady, L.W.Synthesis, antimalarial activity and inhibition of haem detoxification of novel bisquinolines. Bioorg. Med. Chem. Lett., 2001, 11, 2075-77.
21. Dascombe, M.J.; Drew, M.G.B.; Morris, H.; Wilairat, P.; Auparakkitanon, S.; Moule, W.A.; Alizadeh-Shekalgourabi, S.; Evans, P.G.; Lloyd, M.; Anthony M. Dyas, A.M.; Carr, P.; Ismail, F.M.D. Mapping antimalarial pharmacophores as a useful tool for the rapid discovery of drugs effective in vivo: design, construction, characterization, and pharmacology of metaquine. J. Med. Chem., 2005, 48, 5423-36.
22. Fidock, D.A.; Rosenthal, P.J.; Croft, S.L.; Brun, R.; Nwaka, S. Antimalarial drug discovery: efficacy models for compound screening. Nat. Rev. Drug Discov., 2004, 6, 509-20.
23. Jeffrey K. A. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, Elsevier: Amsterdam, 2006.
24. Na-Bangchang, K.; Bray, P.G.; Ward, S.A. Study on the biochemical basis of mefloquine resistant Plasmodium falciparum. Exp. Parasitol., 2007, 117, 141-48.
25. Krishna, S.; Ter Kuile, F.; Supanaranond, W.; Pukrittayakamee, S.; Teja-Isavadharm, P.; Kyle, D.; White, N.J. Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. Br. J. Clin. Pharmacol., 1993, 36, 585-91.
26. Olivier, C.; Rizk, C.; Zhang, D.; Jacqz-Aigrain, E.; Long QTc interval complicating halofantrine therapy in 2 children with Plasmodium falciparum malaria. Arch. Pediatr., 1999, 6, 966-70.
27. Bryson, H.M.; Goa, K.L. Halofantrine. A review of its antimalarial activity, pharmocokinetic properties and therapeutic potential. Drugs, 1992, 43,236-58
28. Weinke, T.; Loscher, T.; Fleischer, K.; Kretschmer, H.; Pohle, H.D.; Kohler, B.; Schlunk, T.; Clemens, R.; Bock, H.L. The efficacy of halofantrine in the treatment of acute malaria in nonimmune travelers. Am. J.Trop. Med. Hyg., 1992, 47, 1-5.
29. Wesche , D.L.; Schuster, B.G.; Wang, W.X.; Woosley, R.L. Mechanism of cardiotoxicity of halofantrine. Clin. Pharmacol. Ther., 2000, 67, 521-29.
30. Nosten, F.; ter Kuile, F.O.; Luxemburger, C.; Woodrow, C.; Kyle, D.E.; Chongsuphajaisiddhi, T.; White, N.J. Cardiac effects of antimalarial treatment with halofantrine. Lancet, 1993, 341, 1054-56.
31. Coker, S.J.; Batey, A.J.; Lightbown, I.D.; Diaz, M.E.; Eisner , D.E. Effects of mefloquine on cardiac contractility and electrical activity in vivo, in isolated cardiac preparations, and in single ventricular myocytes. Br. J. Clin. Pharmacol., 2000, 129, 323-30.
32. Palmer, K.J.; Holiday, S.M.; Brogden, R.N. Mefloquine a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs, 1993, 4, 430-75.
33. Chang, C.; Lin-hua,T.; Jantanavivat, C. Studies on a new antimalarial compound: pyronaridine. Trans. R. Soc. Trop. Med. Hyg., 1992, 86, 7-10.
34. Chen, C.; Tang, L.H.; Jantanavivat, C. Studies on a new antimalarial compound: pyronaridine. Trans. R. Soc. Trop. Med. Hyg., 1992, 86, 7-10.
35. Fu, S.; Xiao, S.H. Pyronaridine: a new antimalarial drug. Parasitol. Today, 1991, 7, 310-13.
36. Ringwald P.; Bickii J.; Basco L. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet, 1996, 347, 24-27.
37. Looareesuwan, S.; Olliaro, P.; Kyle, D.; Wernsdorfer, W. Pyronaridine. Lancet. 1996, 347, 1189-90.
38. Yearick, K.; Ekoue-Kovi, K.; Iwaniuk, D.P.;Natarajan, J.K.; Alumasa, J.; de Dios, A.C.; Roepe, P.D.; Wolf, C. Overcoming drug resistance to heme-targeted antimalarials by systematic side chain variation of 7-Chloro-4-aminoquinolines. J. Med. Chem., 2008, 51, 1995-98.
39. Sherman, J.W. Mechanism of molecular trafficking in malaria. Parasitology, 1988, 96, 857-81.
40. Ginsburg, H. Alterations caused by the intraerythrocytic malaria parasite in the permeability of its host cell membrane. Comp. Biochem. Physiol., 1990, 95, 31-39.
41. Atamna, H.; Krugliuk, M.; Shalmiev, G.; Deho, E.; Pescamona, G.; Ginsburg, H. Mode of Antimalarial effect of methylene blue and some of its analogues on Plasmodium falciparum in culture and their inhibition of P. vinckei petteri and P. yoelii nigeriensis in vivo. Biochem. Pharmacol., 1996, 51, 693-700.
42. Faerbera, P.M.; Arscottb, L.D.; Williams Jr., C.H.; Beckera, K.; Schirmera, R.H. Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue. FEBS Lett. , 1998, 422, 311-14.
43. Vale, N.; Moreira, R.; Gomes, P. Primaquine revisited six decades after its discovery. Eur. J. Med. Chem., 2009, 44(3), 937-953.
44. Arajo, M.J.; Bom, J.; Capela, R.; Casimiro, C.; Chambel, P.; Gomes, P.; Lley, J.; Lopes, F.; Morais, J.; Moreira, R.; de Oliveira, E.; do Rosrio, V.; Vale, N. Imidazolidin-4-one derivatives of primaquine as novel transmission-blocking antimalarials. J. Med. Chem., 2005, 48, 888-92.
45. Crockett, M.; Kain, K.C. Tafenoquine: a promising new antimalarial agent. Expert Opin. Investig. Drugs, 2007, 16, 705-15.
46. Shanks, G.D.; Oloo, A.J.; Aleman, G.M.; Ohrt, C.; Klotz, F.W. Braitman, D.; Horton, J.; Brueckner, R. A new primaquine analogue, tafenoquine (WR238605), for prophylaxis against Plasmodium falciparum malaria. Clin. Infect. Dis., 2001, 33, 1968-74.
47. Greenwood, B.M.; Fidock, D.A.; Kyle, D.E.; Stefan H.I. Kappe, S.H.I.; Alonso, P.L.; Collins, F.H.; Duffy, P.E. Malaria: progress, perils, and prospects for eradication. J. Clin. Invest., 2008, 118, 1266-76.
48. Doherty, J.F.; Sadiq, A.D.; Bayo, L.; Alloueche,A.; Olliaro,P.; Milligan,P.; von Seidlein, L.; Pinder,M. A randomized safety and tolerability trial of artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine- pyrimethamine alone for the treatment of uncomplicated malaria in Gambian childrens. Trans. R. Soc. Trop. Med. Hyg., 1999, 93, 543-46.
49. Ronn, A. M.; Msangeni, H.A.; Mhina, J.; Wernsdorfer, W.H.; Bygbjerg, I.C.; High level of resistance of Plasmodium falciparum to sulfadoxine- pyrimethamine in children in Tanzania. Trans. R. Soc. Trop. Med. Hyg., 1996, 90, 179-81.
50. Tagbor, H.; Bruce, J.; Browne, E.; Randal, A.; Greenwood, B.; Chandramohan, D.; Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomized trial. Lancet, 2006, 368, 1349-56.
51. Hawkins, V.N.; Joshi, H.; Rungsihirunrat, K.; Na-Bangchang, K.; Sibley, C.H.; Antifolates can have a role in the treatment of Plasmodium vivax. Trends Parasitol., 2007, 23, 213-22.
52. Watkins, W.M.; Mberu, E.K.; Winstanley, P.A.; Plowe, C.V.; The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol. Today, 1997, 13, 459-64.
53. McIntosh, H.M.; Greenwood, B.M.; Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine as a treatment for uncomplicated malaria-a systematic review. Ann. Trop. Med. Parasitol., 1998, 93, 265-70.
54. Plowe, C.V.; Kublin, J.G.; Duombo, O.K. P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role in clinical resistance to antifolates. Drug Resist. Updat., 1998, 1, 389-96.
55. Edstein, M.D.; Yeo, A.E.; Kyle, D.E.; Looareesuwan, S.; Wilairatana, P.; Rieckmann, K.H. Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with Atovaquone in vitro. Trans. R. Soc. Trop. Med. Hyg., 1996, 90, 418-21.
56. Meshnick, S. R.; Taylor, T.E.; Kamchonwongpaisan, S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol. Rev., 1996, 60, 301-15.
57. Borstnik, K.; Paik, I. H.; Posner, G. H. Malaria: new chemotherapeutic peroxide drugs. Mini Rev. Med. Chem., 2002, 2, 573-83.
58. Meshnick, S. R. Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol., 2002, 32, 1655-60.
59. Klayman, D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Science, 1985, 228, 1049-55.
60. Hien, T.T.; White, N.J. Qinghaosu. Lancet, 1993, 341, 603-08.
61. Okell, L.C.; Drakeley, C.J.; Bousema, T.;Whitty, C.J.M.; Ghani, A.C. Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS Med., 2008, 5, e226.
62. White, N. Antimalarial drug resistance and combination chemotherapy, Philos. Trans. R. Soc. Lond. B. Biol. Sci., 1999, 354, 739-49.
63. White, N. J. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia, 1999, 41, 301-08.
64. O'Neill, P.M.; Posner, G.H. A medicinal chemistry perspective on artemisinin and related endoperoxides. J. Med. Chem., 2004, 47, 2945-64.
65. Tang, Y.; Dong, Y.; Vennerstrom, J.L. Synthetic peroxides as antimalarials. Med. Res. Rev., 2004, 24, 425-48.
66. Borstnik, K.; Paik, I.H.; Shapiro, T.A.; Posner,G.H. Antimalarial chemotherapeutic peroxides: artemisinin, yingzhaosu A and related compounds. Int. J. Parasitol., 2002, 32, 1661-67.
67. O'Neill, P.M.; Miller, A.; Bishop, L.P.D.; Hindley, S.; Maggs, J.L.; Ward, S.A.; Roberts, S.M.; Scheinmann, F.; Stachulski, A.V.; Posner, G.H.; Park, B.K. Synthesis, antimalarial activity, biomimetic iron(II) chemistry, and in vivo metabolism of novel, potent C-10-phenoxy derivatives of dihydroartemisinin. J. Med. Chem., 2001, 44, 58-68.
68. Posner, G.H.; Parker, M.H.; Northrop, J.; Elias, J.S.; Ploypradith, P.; Xie, S.; Shapiro, T.A. Orally active, hydrolytically stable, semisynthetic, antimalarial trioxanes in the artemisinin Family. J. Med. Chem., 1999, 42, 300-04.
69. Hindley, S.; Ward, S.A.; Storr, R.C.; Searle, N.L.; Bray, P.G.; Park, B.K.; Davies, J.; O'Neill, P.M. Mechanism-based design of parasitetargeted artemisinin derivatives: synthesis and antimalarial activity of new diamine containing analogues. J. Med. Chem., 2002, 45, 1052-63.
70. Meunier, B. Hybrid Molecules with a Dual Mode of Action: Dream or Reality? Acc. Chem. Res., 2008, 41, 69-77.
71. Tang, Y.; Dong, Y.; Vennerstrom, J.L. Synthetic peroxides as antimalarials. Med. Res. Rev., 2004, 24, 425-48.
72. Benoit-Vical, F.; Lelievre, J.; Berry, A.; Deymier, C.; Dechy-Cabaret, O.; Cazelles, J.; Loup, C.; Robert, A.; Magnaval, J.; Meunier, B. Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. Antimicrob. Agents Chemother., 2007, 51, 1463-72.
73. Cosledan, F.; Fraisse, L.; Pellet, A.; Guillou, F.; Mordmuller, B.; Kremsner, P.G.; Moreno, A.; Mazier, D.; Maffrand, J.; Meunier, B. Selection of a trioxaquine as an antimalarial drug candidate. Proc. Natl. Acad. Sci. USA, 2008, 105, 17579- 84.
74. Garah, F.B., Catherine Claparols,C., Benoit-Vical, F., Meunier, B., Robert., A. The Antimalarial Trioxaquine DU1301 Alkylates Heme in Malaria-Infected Mice. Antimicrob. Agents Chemother., 2008, 52, 2966-69.
75. Opsenica, I.; Opsenica, D.; Lanteri, C.A.; Anova, L.; Milhous, W.K.; Smith, K.S.; Solaja, B.A. New chimeric antimalarials with 4-aminoquinoline moiety linked to a tetraoxane skeleton (1). J. Med. Chem., 2008, 51, 6216-19.
76. Sabbani, S.; Stocks, P.A.; Ellis, G.L.; Davies, J.; Hedenstrom, E.; Ward , S.A.; O'Neill, P.M. Piperidine dispiro-1,2,4-trioxane analogues. Bioorg. Med. Chem. Lett., 2008, 18, 5804-08.
77. Posner, G.H.; Jeon, H.B.; Parker, M.H.; Krasavin, M.; Paik, I.H.; Shapiro, T.A. Antimalarial simplified 3-aryltrioxanes: synthesis and preclinical efficacy/toxicity testing in rodents. J. Med. Chem., 2001, 44, 3054-58.
78. Singh, C.; Sharma, U.; Saxenaa, G.; Puri, S.K. Orally active antimalarials: Synthesis and bioevaluation of a new series of steroidbased 1,2,4-trioxanes against multi-drug resistant malaria in mice. Bioorg. Med. Chem. Lett., 2007, 17, 4097-101.
79. Singh, C.; Pandey, S.; Kushwaha, A.K.; Puri, S.K. New fuctionalized 1,2,4-trioxepanes: Synthesis and antimalarial activity against multi-drug resistant P. yoelii in mice. Bioorg. Med. Chem. Lett., 2008, 18, 5190-93.
80. Vennerstrom, J.L.; Arbe-Barnes, S,, Brun, R.; Charman, S.A.; Chiu, F.C.; Chollet, J.; Dong, Y.; Dorn, A.; Hunziker, D.; Matile, H.; McIntosh, K.; Padmanilayam, M.; Santo, Tomas. J.; Scheurer, C.; Scorneaux, B.; Tang, Y.; Urwyler, H.; Wittlin, S.; Charman, W.N. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature, 2004, 430, 900-04
81. O' Neill, P.M. A worthy adversary for malaria. Nature, 2004, 430, 838-39.
82. Uhlemann, A.C.; Wittlin, S.; Matile, H.; Bustamante, L.Y.; Krishna, S. Mechanism of antimalarial action of the synthetic trioxolane RBX11160 (OZ277). Antimicrob. Agents Chemother., 2007, 51, 667-672.
83. http://www.mmv.org/article.php3?id-article=263&recherche=RBx 11160
84. Snyder, C.; Chollet, J.; Santo-Tomas, J.; Scheurer, C.; Wittlin, S. In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. Exp. Parasitol., 2007, 115, 296-300.
85. Dong, Y.; Chollet, J.; Matile, H.; Charman, S.A.; Chiu, F.C.; Charman, W.N.; Scorneaux, B.; Urwyler, H.; Santo Tomas, J.; Scheurer, C.; Snyder, C.; Dorn, A.; Wang, X.; Karle, J.M.; Tang, Y.; Wittlin, S.; Brun, R.; Vennerstrom, J.L. Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable structure-activity relationship using simple prototypes. J. Med. Chem., 2005, 48, 4953-61.
86. Dong, Y.; Tang, Y.; Chollet, J.; Matile, H.; Wittlin, S.; Charman, S.A.; Charman, W.N.; Tomas, J.S.; Scheurer, C.; Snyder, C.; Scorneaux, B.; Bajpai, S.; Alexander, S.A.; Wang, X.; Padmanilayam, M.; Cheruku, S.R.; Brun, R.; Vennerstrom, J.L. Bioorg. Med. Chem., 2006, 14, 6368-82.
87. Tang, Y.; Dong, Y.; Wittlin, S.; Charman, S.A.; Chollet, J.; Chiu, F.C.; Charman, W.N.; Matile, H.; Urwyler, H.; Dorn, A.; Bajpai, S.; Wang, X.; Padmanilayam, M.; Karle, J.M.; Brun, R.; Vennerstrom, J.L.Weak base dispiro-1,2,4-trioxolanes: potent antimalarial ozonides. Bioorg. Med. Chem. Lett., 2007, 17, 1260-65.
88. Meshnick, S.R.; Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol., 2002, 32, 1655-1660.
89. Paitayatat, S.; Tarnchompoo, B.; Thebtaranonth, Y.; Yuthavong, Y. Correlation of antimalarial activity of artemisinin derivatives with binding affinity with ferroprotoporphyrin IX. J. Med. Chem., 1997, 40, 633-38.
90. Vennerstrom, J. L.; Eaton, J. W. Oxidants, oxidant drugs, and malaria. J. Med. Chem. 1988, 31, 1269-77.
91. Vennerstrom, J. L.; Fu, H. N.; Ellis, W. Y.; Ager, A. L., Jr.; Wood, J. K.; Andersen, S. L.; Gerena, L.; Milhous, W. K. Dispiro-1,2,4,5-tetraoxanes: a new class of antimalarial peroxides. J. Med. Chem., 1992, 35, 3023-27.
92. Dong, Y. Synthesis and antimalarial activity of 1,2,4,5-tetraoxanes. Mini Rev. Med. Chem., 2002, 2, 113-23.
93. Dong, Y.; Matile, H.; Chollet, J.; Kaminsky, R.; Wood, J. K.; Vennerstrom, J. L. Synthesis and antimalarial activity of 11 dispiro-1,2,4,5-tetraoxane analogues of WR 148999. 7,8,15,16-Tetraoxadispiro [5.2.5.2] hexadecanes substituted at the 1 and 10 positions with unsaturated and polar functional groups. J. Med. Chem., 1999, 42, 1477-80.
94. Amewu, R.; Stachulski, A.V.; Ward, S.A.; Berry, N.G.; Bray, P.G.; Davies, J.; Labat, G.; Vivasc, L.; O'Neill P.M. Design and synthesis of orally active dispiro 1,2,4,5-tetraoxanes; synthetic antimalarials with superior activity to artemisinin. Org. Biomol. Chem., 2006, 4, 4431-36.
95. McCullough, K. J.; Wood, J. K.; Bhattacharjee, A. K.; Dong, Y.; Kyle, D. E.; Milhous, W. K.; Vennerstrom, J. L. Methyl-substituted dispiro-1,2,4,5- tetraoxanes: correlations of structural studies with antimalarial activity. J. Med. Chem., 2000, 43, 1246-49.
96. Vennerstrom, J. L.; Dong, Y.; Andersen, S. L.; Ager Jr, A. L.; Fu, H.; Miller, R. E.; Wesche, D. L.; Kyle, D. E.; Gerena, L.; Walters, S. M.; Wood, J. K.; Edwards, G.; Holme, A. D.; McLean, W. G.; Milhous, W. K. Synthesis and antimalarial activity of sixteen dispiro-1,2,4, 5-tetraoxanes: alkyl-substituted 7,8,15,16-tetraoxadispiro[ 5.2.5.2]hexadecanes. J. Med. Chem., 2000, 43, 2753-58.
97. Kim, H. S.; Shibata, Y.; Wataya, Y.; Tsuchiya, K.; Masuyama, A.; Nojima, M. Synthesis and antimalarial activity of cyclic peroxides, 1,2,4,5, 7-pentoxocanes and 1,2,4,5-tetroxanes. J. Med. Chem., 1999, 42, 2604-09.
98. Todorovic, N. M.; Stefanovic, M.; Tinant, B.; Declercq, J. P.; Makler, M. T.; Solaja, B. A. Steroidal geminal dihydroperoxides and 1,2,4,5-tetraoxanes: structure determination and their antimalarial activity. Steroids, 1996, 61, 688-96.
99. Opsenica, D.; Pocsfalvi, G.; Juranic, Z.; Tinant, B.; Declercq, J. P.; Kyle, D. E.; Milhous, W. K.; Solaja, B. A. Cholic acid derivatives as 1,2,4,5-tetraoxane carriers: structure and antimalarial and antiproliferative activity. J. Med. Chem., 2000, 43, 3274-82.
100. Opsenica, D.; Kyle, D.E.; Milhous, W. K; Solaja, B. A. Antimalarial, antimycobacterial and antiproliferative activity of phenyl substituted mixed tetraoxanes. J. Serb. Chem. Soc. 2003, 68, 291-302.
101. Olaja, B.A.; Terzi, N.; Pocsfalvi,G.; Gerena, L.; Tinant, B.; Opsenica, D.; Milhous.;W.K. Antimalarial and antimycobacterial activity. J. Med. Chem., 2002, 45, 3331-36.
102. Zmitek, K.; Stavber, S.; Zupan, M.; Bonnet-Delpon, D.; Charneau, S.; Grellier, P.; Iskra, J. Synthesis and antimalarial activities of novel 3,3,6,6-tetraalkyl-1,2,4,5-tetraoxanes. Bioorg. Med. Chem. Lett., 2006, 14, 7790-95.
103. Phillips, M.A.; Gujjar, R.; Malmquist, N.A.; White, J.; El Mazouni, F.; Baldwin, J.; Rathod ,P.K. Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the Malaria Parasite Plasmodium falciparum. J. Med. Chem., 2008, 51, 3649-53.
104. Sanchez-Delgado, R.A.; Anzellotti, A. Metal complexes as chemotherapeutic agents against tropical diseases: trypanosomiasis, malaria and leishmaniasis. Mini Rev. Med. Chem., 2004, 4, 23-30.
105. Navarro, M.; Pekerar, S.; Perez, H.A. Synthesis, characterization and antimalarial activity of new iridium-chloroquine complexes. Polyhedron, 2007, 26, 2420-24.
106. Ajibade, P.A. Metal complexes in the management of parasitic diseases: in vitro antiprotozoal studies of metal complexes of some antimalarial drugs. Curr. Sci., 2008, 95, 1673.
107. Ajibade, P.A.; Kolawole,G.A. Synthesis, characterization and antiprotozoal studies of some metal complexes of antimalarial drugs. Transition Met. Chem., 2008, 33, 493-97.
108. Gemma, S.; Campiani, G.; Butini, S.; Kukreja, G.; Joshi, B.P.; Persico, M.; Catalanotti, B.; Ettore Novellino, E.; Fattorusso, E.; Nacci, V.; Savini, L.; Taramelli, D.; Basilico, N.; Morace, G.; Yardley, V.; Fattorusso, C. Design and synthesis of potent antimalarial agents based on clotrimazole scaffold: exploring an innovative pharmacophore. J. Med. Chem., 2007, 50, 595-98.
109. Gemma, S.; Campiani, G.; Butini, S.; Kukreja, G.; Coccone, S.S.; P. Joshi, B.P.; Persico, M.; Nacci, V.; Fiorini, I.; Novellino, E.; Fattorusso, E.; Scafati, O.T.; Savini, L.; Taramelli, D.; Basilico, N.; Parapini, S.; Morace, G.;Yardley, V.; Croft,S.; Coletta, M.; Marini, S.; Fattorusso, C.; Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies. J. Med. Chem., 2008, 51, 1278-94.
110. Skytte, D.M.; Nielsen, S.F.; Chen, M.; Zhai, L.; Olsen, C.E.; Christensen, S.B. Antimalarial and antiplasmodial activities of norneolignans. Syntheses and SAR. J. Med. Chem., 2006, 49, 436-40.
111. Skytte, D.M.; Rasmussen, H.B.; Christensen, S.B. Carroll rearrangement to construct the norneolignan skeleton. Nat. Prod. Res., 2008, 22, 116-23.
112. Jones, S.M.; Urch, J.E.; Kaiser, M.; Brun, R.; Harwood, J.L.; Berry, C.; Gilbert, I.H. Analogues of thiolactomycin as potential antimalarial agents. J. Med. Chem., 2005, 48, 5932-41.
113. Fotie, J.; Morgan, R.E. Depsipeptides from microorganisms: a new class of antimalarials. Mini Rev. Med. Chem., 2008, 8, 1088-94.
114. Chen, M.; Theander, T.G.; Christensen, S.B.; Hviid, L.; Zhai, L.; Kharazmi, A. Licochalcone A, a new antimalarial agent, inhibits in vitro growth of the human malaria parasite Plasmodium falciparum and protects mice from P. yoelii infection. Antimicrob. Agents Chemother., 1994, 38, 1470-75.
115. Li, R.; Chen, X.; Gong, B.; Dominguez, J.N.; Davidson, E.; Kurzban, G.; Miller, R.E.; Nuzum, E.O.; Rosenthal, P.J. In vitro antimalarial activity of chalcones and their derivatives. J. Med. Chem., 1995, 38, 5031-37.
116. Liu, M.; Wilairat, P.; Go, M.L.; Antimalarial alkoxylated and hydroxylated chalones: structure-activity relationship analysis. J. Med. Chem., 2001, 44, 4443-52.
117. Domnguez, J.N.; Len, C.; Rodrigues, J.; de Domnguez, N.G.; Gut, J.; Rosenthal, P.J. Synthesis and evaluation of new antimalarial phenylurenyl chalcone derivatives. J. Med. Chem., 2005, 48, 3654-58.
118. Ang, K.K.H.; Holmes, M.J.; Higa, T.; Hamann, M.T.; Kara, U.A.K. In vivo antimalarial activity of the beta-carboline alkaloid manzamine A. Antimicrob. Agents Chemother., 2000, 44, 1645-49.
119. Laport, M.S.; Santos, O.C.; Muricy, G. Marine sponges: potential sources of new antimicrobial drugs. Curr. Pharm. Biotechnol., 2009, 10, 86-105.
120. Winkler,J.D.; Londregan,A.T.;Hamann, M.T. Antimalarial activity of a new family of analogues of manzamine A. Org. Lett., 2006, 8 , 2591-94.
121. Prudhomme, J.; McDaniel, E.; Ponts, N.; Bertani, S.; Fenical, W.; Jensen,P.; Roch, K.L. Marine actinomycetes: A new source of compounds against the human malaria parasite. PLoS One, 2008, 3, e2335.
122. Laurent, D.; Jullian, V.; Parenty, A.; Knibiehler, M.; Dorin, D.; Schmitt, S.; Lozach, O.; Lebouvier, N.; Frostin, M.; Alby, F.; Maurel, S.; Doerig, C.; Meijerf, L.; Sauvain, M. Antimalarial potential of xestoquinone, a protein kinase inhibitor isolated from a Vanuatu marine sponge Xestospongia sp. Bioorg. Med. Chem., 2006, 14, 4477-82.
123. Desoubzdanne, D.; Marcourt, L.; Raux, R.; Chevalley, S.; Dorin, D.; Doerig, C.;Valentin, A.; Ausseil, F.; Debitus, C. Alisiaquinones and alisiaquinol, dual inhibitors of Plasmodium falciparum enzyme targets from a new Caledonian deep water sponge. J. Nat. Prod., 2008, 71, 1189-92.
124. Fattorusso,E.; Parapini, S.; Campagnuolo,C.; Basilico,N.; Scafati, O.T.; Taramelli, D. Activity against Plasmodium falciparum of cycloperoxide compounds obtained from the sponge Plakortis simplex. J. Antimicrob. Chemother., 2002, 50, 883-88.
125. Fattorusso, C.; Campiani, G.; Catalanotti, B.; Persico, M.; Basilico, N.; Parapini, S.; Donatella Taramelli,D.; Campagnuolo, C.; Fattorusso, E.; Adriana Romano, A.; Scafati, O.T. Endoperoxide derivatives from marine organisms: 1,2-dioxanes of the plakortin family as novel antimalarial agents. J. Med. Chem., 2006, 49, 7088-94.
126. Agli, M.D.; Parapini, S.; Galli, G.; Vaiana, N.; Taramelli, D.; Sparatore, A.; Liu, P.; Dunn, B.M.; Bosisio, E.; Romeo, S. High antiplasmodial activity of novel plasmepsins I and II inhibitors. J. Med. Chem., 2006, 49, 7440-49.
127. Ersmark, K.; Samuelsson,B.; Hallberg, A.; Plasmepsins as potential targets for new antimalarial therapy. Med. Res. Rev., 2006, 26, 626-66.
128. World Health Organization, Chemotherapy of malaria and resistance to antimalarials. Report of a WHO scientific group. WHO technical report series, No. 529. Geneva, 1973.
129. Bruce-Chwatt, L. J.; Black, R. H.; Canfield, C. J.; Clyde, D. F.; Peters, W.; Wernsdorfer, W. H. Chemotherapy of Malaria, Geneva, World Health Organization, 1986.
130. Zhong, D.; Afrane, Y.; Githeko, A.; Cui, L.; Menge, D.M.; Yan, G. Molecular epidemiology of drug-resistant malaria in western Kenya Highlands. BMC Infect. Dis., 2008, 8, 105.
131. Baird, J.K. Effectiveness of antimalarial drugs. N. Engl. J. Med., 2005, 352, 1565-77.
132. Snow, R.W.; Guerra, C.A.; Noor A.M.; Myint H.Y.; Hay S. I. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature, 2005, 434, 214-7.
133. Ekland, E.H.; Fidock, D.A. Advances in understanding the genetic basis of antimalarial drug resistance. Curr. Opin. Microbiol., 2007, 10, 363-70.
134. Hayton, K.; Su, X.Z. Genetic and biochemical aspects of drug resistance in malaria parasites. Curr. Drug Targets Infect. Disord., 2004, 4, 1-10.
135. Barnes, K.I.; Watkins, W.M.; White, N.J. Antimalarial dosing regimens and drug resistance. Trends Parasitol., 2008, 24, 127-34.
136. Sibley, C.H.; Ringwald, P. A database of antimalarial drug resistance. Malar. J., 2006, 5, 48.
137. Wernsdorfer, W.H. The development and spread of drug resistant malaria. Parasitol. Today, 1991, 7, 297-303.
138. Verdrager, J. Epidemiology of the emergence and spread of drugresistant falciparum malaria in South-East Asia and Australasia. J. Trop. Med. Hyg., 1986, 89, 277-89.
139. Martinelli, A.; Moreira, R.; Cravo, P.V.L. Malaria combination therapies: advantages and shortcomings. Mini Rev. Med. Chem., 2008, 8, 201-12.
140. Blanchard, T. J.; Mabey, D.C.; Hunt-Cooke, A.; Edwards, G.; Hutchinson, D.B.; Benjamin, S.; Chiodini, P.L. Multiresistant falciparum malaria cured using atovaquone and proguanil. Trans. R. Soc. Trop. Med. Hyg., 1994, 88, 693.
141. Looareesuwan, S.; Wilairatana, P.; Chalermarut,K.; Rattanapong, Y.; Canfield, C.J.; Hutchinson, D.B. Efficacy and safety of atovaquone/ proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg., 1999, 60, 526-32.
142. Radloff, P. D.; Philipps, J.; Hutchinson, D.; Kremsner, P.G. 1996, Atovaquone plus proguanil is an effective treatment for Plasmodium ovale and P. malariae malaria. Trans. R. Soc. Trop. Med. Hyg., 1996, 90, 682.
143. McKeage, K.; Scott, L. J. Atovaquone/proguanil. Drugs, 2003, 63, 597-623.
144. Looareesuwan, S.; Viravan, C.; Webster, H.K.; Kyle, D.E.; Hutchinson, D.B.; Canfield, C.J. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs for the treatment of acute uncomplicated malaria in Thailand. Am. J. Trop. Med. Hyg., 1996, 54, 62-66.
145. Kevin, S.G.; Linda, S.L.; Sonja, M.; Monica, E.P. Treatment of malaria in the United States: a systematic review. JAMA, 2007, 297, 2264-77.
146. Watkins, W.M.; Brandling-Bennett, A.D.; Nevill, C.G.; Carter, J.Y.; Boriga, D.A.; Howells, R.E.; Koech, D.K. Chlorproguanil/dapsone for the treatment of non-severe Plasmodium falciparum infection in Kenya: a pilot study. Trans. R. Soc. Trop. Med. Hyg., 1988, 82, 398-403.
147. Amukoye, E.; Winstanley, P.A.; Watkins, W.M.; Snow, R.W.; Hatcher, J.; Mosobo, M,.; Ngumbao, E.; Lowe, B.; Ton, M.; Minyiri, G.; Marsh, K. Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria. Antimicrob. Agents Chemother., 1997, 41, 2261-64.
148. Sulo, J.; Chimpeni, P.; Hatcher, J.; Kublin, J.G.; Plowe, C.V.; Molyneux, M.E.; Marsh, K.; Taylor, T.E.; Watkins, W.M.; Winstanley, P.A. Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet, 2002, 360, 1136-43.
149. Lang, T.; Greenwood, B.; The development of Lapdap, an affordable new treatment for malaria. Lancet Infect. Dis., 2003, 3, 62-68.
150. Yeung, S.; Pongtavornpinyo, W.; Hastings, I.M.; Mills, A.J.; White, N.J. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am. J. Trop. Med. Hyg., 2004, 71, 179-186.
151. Nosten, F.; White, N.J. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg., 2007, 77, 181-92.
152. Mutabingwa, T.K. Artemisinin-based combination therapies (ACTs): Best hope for malaria treatment but inaccessible to the needy. Acta Trop., 2005, 95, 305-15.
153. White, N.J.; Olliaro, P.L. Strategies for prevention of antimalarial drug resistance: rationale for combination therapy for malaria. Parasitol. Today, 1996, 12, 399-401.
154. Von Seidlein, L.; Milligan, P.; Pinder, M.; Bojang, K.; Anyalebechi, C.; Gosling, R.; Coleman, R.; Ude, J.I.; Sadiq, A.; Duraisingh, M.; Warhurst, D.; Alloueche, A.; Targett, G.; McAdam, K.; Greenwood, B.; Walraven, G.; Olliaro, P.; Doherty, T. Efficacy of artesunate plus pyrimethamine-sulfadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet, 2000, 355, 352-57.
155. Tjitra, E.; Baker, J.; Suprianto, S.; Cheng, Q.; Nicholas, M. Anstey. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Antimicrob. Agents Chemother., 2002, 46, 3947-53.
156. Tall, A.; Rabarijaona, L.P.; Robert, V.; Bedja, S.A.; Ariey, F.; Randrianarivelojosia, M. Efficacy of artesunate plus amodiaquine, artesunate plus sulfadoxine-pyrimethamine, and chloroquine plus sulfadoxinepyrimethamine in patients with uncomplicated Plasmodium falciparum in the Comoros Union site. Acta Trop., 2007, 102, 176-81.
157. Olliaro, P.L.; Trigg, P.I. Status of antimalarial drugs under development. Bull.World Health Organ., 1995, 73, 565-71.
158. Vugt, M.V.; Wilairatana, P.; Gemperli, B.; Gathmann, I.; Phaipun, L.; Brockman, A.; Luxemburger, C.; White, N.J.; Nosten, F.; Looareesuwan, S. Efficacy of six doses of artemether-lumefantrine (Benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg., 1999, 60, 936-42.
159. Vugt, M.V.; A. Brockman, A.; Gemperli, B.; Luxemburger, C.; Gathmann, I.; Royce, C.; Slight, T.; Looareesuwan, S.; White, N.J.; Nosten, F. A randomised comparison of artemether-benflumetol and artesunate-mefloquine in the treatment of multidrug-resistant falciparum malaria. Antimicrob. Agents Chemother., 1998, 42, 135-39.
160. Vugt, M.V.; Looareesuwan, S.; Wilairatana, P.; McGready, R.; Villegas, L.; Gathmann, I.; Mull, R.; Brockman, A.; White, N.J.; Nosten, F. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans. R. Soc. Trop. Med. Hyg., 2000, 94, 545-548.
161. Ezzet, F.; Vugt, M.V.; Nosten, F.; Looareesuwan, S.; White N.J. Pharmacokinetics and pharmacodynamics of lumefantrine (Benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother., 2000, 44, 697-704.
162. White, N.J.; Nosten, F.; Looareesuwan, S.; Watkins, W.M.; Marsh, K.; Snow, R.W.; Kokwaro, G.; Ouma, J.; Hien, T.T.; Molyneux, M.E.; Taylor, T.E.; Newbold, C.I.; Ruebush, T.K.; Danis, M.; Greenwood, B.M.; Anderson, R.M.; Olliaro, P. Averting a malaria disaster. Lancet, 1999, 353, 1965-67.
163. Price, R.N.; Nosten, F.; Luxemburger, C.; ter Kuile, F.O.; Paiphun, L.; Chongsuphajaisiddhi, T.; White, N.J. Effects of artemisinin derivatives on malaria transmissiblity. Lancet, 1996, 347, 1654-58.
164. Lefevre, G.; Thomsen, M.S. Clinical pharmacokinetics of artemether and lumefantrine (Riamet). Clin. Drug Invest., 1999,18, 467-80.
165. Bakshi, R.; Hermeling-Fritz, I.; Gathmann, I.; Alteri, E. An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Trans. R. Soc. Trop. Med. Hyg., 2000, 94,419-24.
166. Wiesner, J.; Henschker, D.; Hutchinson, D.B.; Beck, E.; Jomaa, H. In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin. Antimicrob. Agents Chemother., 2002, 46, 2889-94.
167. DeHaan, R. M.; Metzler, C. M.; Schellenberg, D.; VandenBosch, W.D.; Masson, E.L. Pharmacokinetic studies of clindamycin hydrochloride in humans. Int. J. Clin. Pharmacol., 1972, 6, 105-19.
168. Oyakhirome, S.; Issifou, S.; Pongratz, P.; Barondi, F.; Ramharter, M.; Kun, J.F.; Missinou, M.A.; Lell, B.; Kremsnerm, P.G. Randomized controlled trial of fosmidomycin-clindamycin versus sulfadoxine-pyrimethamine in the treatment of Plasmodium falciparum malaria. Antimicrob. Agents Chemother., 2007, 51, 1869-71.
169. Na-Bangchang, K.; Ruengweerayut, R.; Karbwang, J.; Chauemung, A.; Hutchinson, D. Pharmacokinetics and pharmacodynamics of fosmidomycin monotherapy and combination therapy with clindamycin in the treatment of multidrug resistant falciparum malaria. Malar. J., 2007, 6, 70-79.
170. Chaudhuri, R.; Ahmed, S.; Ansari, F.A.; Singh, H.V.; Ramachandran, S. MalVac: database of malarial vaccine candidates. Malar. J., 2008, 7, 184-90.
171. http://www.who.int/vaccine-research/documents/Malaria%20Vacci ne%20Rainbow%20Table-Clinical-Oct-2008.pdf.